Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer

Expert Review of Anticancer Therapy

Volumn 12, Issue 1, 2012, Pages 1-3

  Bedoya, Diego J ^a   Mitsiades, Nicholas ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

abiraterone; androgen ablation therapy; androgen receptor; androgen deprivation therapy; castration resistant prostate cancer; combination therapy; CYP17; drug resistance; MDV3100; prostate cancer

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; ANDROGEN RECEPTOR; ANDROSTANOLONE; GONADORELIN ASSOCIATED PEPTIDE DERIVATIVE; ORTERONEL; PLACEBO; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; DRUG RESPONSE; HUMAN; REVIEW; SIGNAL TRANSDUCTION; TESTOSTERONE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ANDROGEN ANTAGONISTS; ANDROGEN RECEPTOR ANTAGONISTS; ANDROGENS; ANDROSTADIENES; CLINICAL TRIALS, PHASE III AS TOPIC; ENZYME INHIBITORS; GLUCOCORTICOIDS; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STEROID 17-ALPHA-HYDROXYLASE;

EID: 83455236514     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.196     Document Type: Review

References (20)

1. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol. 10(10), 981-991 (2009).
2. Holzbeierlein J, Lal P, LaTulippe E et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol. 164(1), 217-227 (2004).
3. Attard G, Reid AH, A'Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27(23), 3742-3748 (2009).
4. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 23(32), 8253-8261 (2005).
5. Scher HI, Beer TM, Higano CS et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a Phase 1-2 study. Lancet 375(9724), 1437-1446 (2010).
6. Mostaghel EA, Page ST, Lin DW et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 67(10), 5033-5041 (2007).
7. Ohlson N, Wikstrom P, Stattin P, Bergh A. Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment. Prostate 62(4), 307-315 (2005).
8. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 61(7), 2892-2898 (2001).
9. Pfeiffer MJ, Smit FP, Sedelaar JP, Schalken JA. Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol. Med. 17(7-8), 657-664 (2011).
10. Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928), 787-790 (2009).
11. Locke JA, Guns ES, Lubik AA et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68(15), 6407-6415 (2008).
12. Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68(11), 4447-4454 (2008).
13. Pelletier G. Expression of steroidogenic enzymes and sex-steroid receptors in human prostate. Best Pract. Res. Clin. Endocrinol. Metab. 22(2), 223-228 (2008).
14. Stanbrough M, Bubley GJ, Ross K et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66(5), 2815-2825 (2006).
15. Hofland J, van Weerden WM, Dits NF et al. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res. 70(3), 1256-1264 (2010).
16. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364(21), 1995-2005 (2011).
17. Dreicer R, Agus DB, MacVicar GR et al. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: a Phase I/II, open-label study. J. Clin. Oncol. (Meeting Abstracts) 28, 3084 (2010).
18. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 68(13), 5469-5477 (2008).
19. Mostaghel EA, Marck BT, Plymate SR et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin. Cancer Res. 17(18), 5913-5925 (2011).
20. Watson PA, Chen YF, Balbas MD et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc. Natl Acad. Sci. USA 107(39), 16759-16765 (2010).